FibroGen, Inc.
FGEN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $21,423 | $782,394 | $1,334,989 |
| - Cash | $117,975 | $23,367 | $33,609 | $50,482 |
| + Debt | $19,471 | $93,131 | $73,419 | $73,092 |
| Enterprise Value | – | $91,187 | $822,204 | $1,357,599 |
| Revenue | $1,076 | $1,348 | $2,739 | -$123,256 |
| % Growth | -20.2% | -50.8% | 102.2% | – |
| Gross Profit | $1,134 | $1,263 | $2,487 | -$102,590 |
| % Margin | 105.4% | 93.7% | 90.8% | 83.2% |
| EBITDA | -$10,871 | -$11,545 | -$14,180 | -$91,100 |
| % Margin | -1,010.3% | -856.5% | -517.7% | 73.9% |
| Net Income | $200,636 | -$7,603 | $4,639 | $17,982 |
| % Margin | 18,646.5% | -564% | 169.4% | -14.6% |
| EPS Diluted | 49.61 | -1.88 | 0.05 | 4.5 |
| % Growth | 2,738.8% | -3,860% | -98.9% | – |
| Operating Cash Flow | -$1,847 | $12,682 | $2,719 | -$30,466 |
| Capital Expenditures | -$9 | -$13 | -$16 | -$141 |
| Free Cash Flow | -$1,856 | $12,669 | $2,703 | -$30,607 |